Existing backer Bristol Myers Squibb returned to commit to healthcare venture firm BioGeneration Ventures' oversubscribed BGV IV vehicle.
Netherlands-based, healthcare-focused venture capital firm BioGeneration Ventures closed its fourth fund yesterday having raised €105m ($119m) from limited partners including pharmaceutical firm Bristol Myers Squibb (BMS).
BMS and fellow existing backers Schroder Adveq and the European Investment Fund (EIF) joined newly minted LPs including Industriens Pension and KfW Capital in contributing to the oversubscribed BGV IV.
Founded in 2006, BioGeneration Ventures invests in seed and early-stage pharmaceutical developers working on drugs with convincing experimental data as their basis.
The firm…
